Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Thread starter U.S. News
Start date Feb 5, 2026

U.S. News

Guest

Feb 5, 2026

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Prefix: N/A

Forum: USA News

Start date: Feb 5, 2026

Last reply date: Feb 5, 2026

Replies: 0

Thread Tags

Thread statistics

Created: U.S. News, Feb 5, 2026

Replies: 0

Views: 1

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search